News
- Author:
- Will Pass
Publish date: May 3, 2019
Systemic treatments have altered the disease kinetics for patients with melanoma.
News
- Author:
- Will Pass
Publish date: May 1, 2019
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
News
- Author:
- Will Pass
Publish date: April 26, 2019
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However, in...
News
- Author:
- Will Pass
Publish date: April 25, 2019
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550 patients...
News
- Author:
- Will Pass
Publish date: April 25, 2019
The Brigham and Women’s Hospital tumor classification system was better than the AJCC 8 in predicting metastases and death among 459 patients with ...
News
- Author:
- Will Pass
Publish date: April 25, 2019
GLASGOW – The registry-based study showed that more than 70% of patients who presented with thrombotic thrombocytopenic purpura had neurological ab...
News
- Author:
- Will Pass
Publish date: April 24, 2019
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central nerv...
News
- Author:
- Will Pass
Publish date: April 24, 2019
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as ...
News
- Author:
- Will Pass
Publish date: April 24, 2019
GLASGOW – A survey of chronic myeloid leukemia patients taking tyrosine kinase inhibitors (TKIs) revealed that more than one-third were taking comp...
News
- Author:
- Will Pass
Publish date: April 23, 2019
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those receivin...
News
- Author:
- Will Pass
Publish date: April 23, 2019
Patients who have recurrence of cutaneous squamous cell cancer of the head and neck (cSCC-HN) tend to have poor outcomes regardless of immune statu...
News
- Author:
- Will Pass
Publish date: April 23, 2019
Emicizumab was effective as a monthly treatment for patients with hemophilia A, both with and without inhibitors, according to an ongoing phase 3 t...
News
- Author:
- Will Pass
Publish date: April 22, 2019
GENEVA – The overall response rate was 55% for patients with NSCLC and leptomeningeal metastases receiving osimertini...
News
- Author:
- Will Pass
Publish date: April 19, 2019
Patients undergoing head and neck radiotherapy who used mouthwash had lower pain scores, compared with placebo, but clinical thresholds weren’t met...
News
- Author:
- Will Pass
Publish date: April 18, 2019
GLASGOW – Researchers presented early results from the PADDOCK and PLAUDIT trials, showing that APL-2 significantly increased hemoglobin levels for...
